160 related articles for article (PubMed ID: 18045949)
1. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy.
Riesco-Eizaguirre G; Santisteban P
Endocr Relat Cancer; 2007 Dec; 14(4):957-77. PubMed ID: 18045949
[TBL] [Abstract][Full Text] [Related]
2. How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer.
Couto JP; Prazeres H; Castro P; Lima J; Máximo V; Soares P; Sobrinho-Simões M
J Clin Pathol; 2009 May; 62(5):414-21. PubMed ID: 19147628
[TBL] [Abstract][Full Text] [Related]
3. Genetic mutations in thyroid carcinoma.
Taccaliti A; Boscaro M
Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
[TBL] [Abstract][Full Text] [Related]
4. [Molecular mechanism of thyroid carcinogenesis].
Yamashita S; Mitsutake N
Nihon Rinsho; 2007 Nov; 65(11):1959-65. PubMed ID: 18018555
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathogenesis of follicular cell derived thyroid cancers.
Parameswaran R; Brooks S; Sadler GP
Int J Surg; 2010; 8(3):186-93. PubMed ID: 20097316
[TBL] [Abstract][Full Text] [Related]
6. Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations.
Salvatore G; Chiappetta G; Nikiforov YE; Decaussin-Petrucci M; Fusco A; Carney JA; Santoro M
Eur J Cancer; 2005 Mar; 41(5):816-21. PubMed ID: 15763659
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy: a new hope for thyroid carcinomas.
Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
[TBL] [Abstract][Full Text] [Related]
8. Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.
Kojic KL; Kojic SL; Wiseman SM
Expert Rev Anticancer Ther; 2012 Mar; 12(3):345-57. PubMed ID: 22369326
[TBL] [Abstract][Full Text] [Related]
9. [Genetic abnormality in thyroid cancers].
Yamashita S
Nihon Rinsho; 2005 Oct; 63 Suppl 10():159-62. PubMed ID: 16279621
[No Abstract] [Full Text] [Related]
10. New molecular targeted therapies in thyroid cancer.
Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
[TBL] [Abstract][Full Text] [Related]
11. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
12. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
13. [Gene abnormalities in thyroid cancer].
Namba H; Yamashita S
Nihon Rinsho; 2007 Nov; 65(11):1967-72. PubMed ID: 18018556
[TBL] [Abstract][Full Text] [Related]
14. Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer.
Santoro M; Carlomagno F
Nat Clin Pract Endocrinol Metab; 2006 Jan; 2(1):42-52. PubMed ID: 16932252
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical localisation of RET and p53 mutant protein of thyroid lesions in a North-Eastern Malaysian population and its prognostic implications.
Omar E; Madhavan M; Othman NH
Pathology; 2004 Apr; 36(2):152-9. PubMed ID: 15203751
[TBL] [Abstract][Full Text] [Related]
16. Molecular events in follicular thyroid tumors.
Kroll TG
Cancer Treat Res; 2004; 122():85-105. PubMed ID: 16209039
[TBL] [Abstract][Full Text] [Related]
17. [Pathological and clinical features of malignant thyroid tumors: classification, immunohistology, prognostic criteria].
Schröder S
Veroff Pathol; 1988; 130():1-159. PubMed ID: 3213226
[TBL] [Abstract][Full Text] [Related]
18. Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.
Lubitz CC; Sadow PM; Daniels GH; Wirth LJ
Thyroid; 2021 Oct; 31(10):1451-1462. PubMed ID: 33860688
[No Abstract] [Full Text] [Related]
19. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.
Fagin JA
J Endocrinol; 2004 Nov; 183(2):249-56. PubMed ID: 15531713
[TBL] [Abstract][Full Text] [Related]
20. Modeling anaplastic thyroid carcinoma in the mouse.
Champa D; Di Cristofano A
Horm Cancer; 2015 Feb; 6(1):37-44. PubMed ID: 25420535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
